Parkinson disease (PD) is a progressive neurodegenerative disease characterized by motor, cognitive, and psychiatric manifestations resulting from abnormal protein deposition and neurotransmitter deficits. The variability in clinical presentation and progression likely reflects the underlying variability in brain pathology. Although current treatments provide dramatic motor benefit in PD, they fail to alleviate some aspects of gait impairment and non-motor symptoms and may exacerbate cognitive and psychiatric features. To develop more ?personalized medicine? interventions to treat, forestall or prevent these features, classification of PD clinical subtypes and identification of the associated biological mechanisms are necessary for patient stratification, predicting progression, development and evaluation of novel treatments. Therefore, we propose to identify and validate PD clinical subtypes based on comprehensive motor, cognitive, and psychiatric evaluations; determine the predictive utility of PD clinical subtypes through longitudinal behavioral assessments; and examine biological markers of the PD clinical subtypes from multimodal neuroimaging, CSF, and autopsy data.

Public Health Relevance

Individuals with Parkinson disease (PD) often develop a combination of motor, cognitive, and psychiatric problems that adds substantial morbidity, mortality and economic burden to patients, families and society. In order to develop and evaluate more personalized interventions, information about possible subtypes, clinical progression, and biological mechanisms are needed. This study will identify PD subtypes and compare clinical progression and biological measures across subtypes, thus yielding methods for patient stratification, targets for treatment intervention, and the ability to predict PD progression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS097437-02
Application #
9437860
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Babcock, Debra J
Project Start
2017-04-01
Project End
2022-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Washington University
Department
Neurology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Milchenko, Mikhail; Snyder, Abraham Z; Campbell, Meghan C et al. (2018) ESM-CT: a precise method for localization of DBS electrodes in CT images. J Neurosci Methods 308:366-376
Maiti, Baijayanta; Perlmutter, Joel S (2018) PET Imaging in Movement Disorders. Semin Nucl Med 48:513-524
Gratton, Caterina; Koller, Jonathan M; Shannon, William et al. (2018) Emergent Functional Network Effects in Parkinson Disease. Cereb Cortex :
Jinnah, H A; Comella, Cynthia L; Perlmutter, Joel et al. (2018) Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon 147:89-95
Milchenko, Mikhail; Norris, Scott A; Poston, Kathleen et al. (2018) 7T MRI subthalamic nucleus atlas for use with 3T MRI. J Med Imaging (Bellingham) 5:015002